Ascentage Pharma Company

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Leveraging their expertise in structure-based drug design and their innovative drug discovery engine, they have developed a robust pipeline of seven drug candidates that disruptcomplex and difficult-to-target protein-protein interactions (PPIs), and next-generation tyrosine kinase inhibitors (TKIs). Their PPI drug candidates are designed to treat cancer and other diseases by restoring the normal function of key apoptotic pathways, including the Bcl-2/Bcl-xL, MDM2-p53 and IAP pathways, which play a pivotal role in regulating apoptosis. They are also developing next-generation TKIs to treat diseases for high unmet medical needs.

Investors

Headquarters: China
Total Funding: 2,37E+08
Founded Date: 2009
Employee Number: 101-250
Last Funding Type: Series C
Investor Type: For Profit
Investors Number: 13
Last Funding Date: 2018-07-17
Technology: Geroscience
Funding Status: Late Stage Venture
Estimated Revenue: $10M to $50M
Industry: Apoptosis
Register and Claim Ownership